GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

Mississauga, Ontario Tuesday, May 27, 2025, 16:00 Hrs [IST] ...

The global Healthcare Contract Manufacturing Market size is projected to be valued at USD 183.7 billion in 2023 and reach USD 347.5 billion by 2030, growing at a CAGR of 9.5% according to a new report ...

Journalists and news professionals across Canada today are launching an industry-wide mental health support program to combat stress, burnout and trauma exposure. Twenty volunteers were trained this ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

Despite its profile as a long-acting IL-5 receptor antagonist with convenient semiannual dosing, GSK's depemokimab, the most advanced asthma pipeline asset, has generated relatively limited ...

Two of the treatments that will be receiving plenty of attention in GSK’s presentations are mepolizumab and depemokimab, which are both monoclonal antibodies (mAbs) that target IL-5, a key cytokine or ...

Emma Walmsley, Chief Executive Officer, GSK, said, "We are very focused on preparing for launches of Blenrep, Nucala and depemokimab, and pivotal trials for potential new medicines in respiratory ...

GSK is opening the door to a new era in urinary ... plus a new launch for biologic depemokimab. All five should help the company achieve its recently increased 2031 sales goal of more than 40 ...

Daniel J. Jackson In the previous phase 3 SWIFT-1/2 studies, two doses of depemokimab (GSK) administered at week 0 and 26 in addition to standard of care reduced asthma exacerbations by ...

GSK. “Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress interleukin-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of ...